Caregivers in the US are burned out: We explore the opportunity healthcare and pharma brands have to create marketing strategies specifically tailored to caregivers.
Docs use genAI to appeal denied prior authorizations: Here’s why physicians are turning to the tech for appeals and where we think the prior authorization standoff between insurers and providers is headed.
Pfizer is developing a once-a-day oral GLP-1: Two drugmakers control the weight loss drug market—for now. Here's who could benefit the most from more players in the space.
FDA revises guidance to help drug- and device-makers address social media misinformation: But we’re not sure the regulator has the appetite to take on more authority related to healthcare and pharma social media ads.
FTC to sue PBMs over drug pricing tactics: Could pharmacy benefit managers’ power over negotiating drug prices start to diminish?
GLP-1 drugs from Novo, Lilly go head to head in clinical study: We explore the findings and their impact on the broader weight loss drug market.
OpenAI’s CEO, Arianna Huffington launch startup: It may take some time for the new venture’s AI-based personalized health coach to realize its full potential. Here’s why.
Strengthened features for user data analysis could help increase Oura’s adoption in the wearables market and justify its cost.
Samsung unveils smartwatch feature that isn’t available on Apple Watch: Here’s how the new health-tracking feature works and why the specter of Apple looms large for Samsung in the health wearables space.
Our top 5 articles in H1 2024: Consumers’ media habits, patients’ healthcare spending, and Big Pharma drew the most attention from our digital health audience.
What do doctors think of at-home diagnostic tests? We explore what it will take for the market to evolve even further.
FTC investigates Teva over drug patents: The drugmaker isn’t going down without a fight. Market competition and Rx prices are on the line.
Health insurers are covering fewer prescription drugs: We unpack new Rx spending data from GoodRx and explore what it means for patients.
Gen Xers and millennials are worried about the future of Medicare: But they aren’t educated on what the program provides. We explore the opportunity for marketers.
Report raises questions about Hims & Hers’ new GLP-1 offering: We examine how the chaotic weight-loss drug market has become a slippery slope for some players in the space.
How health plans can improve members’ satisfaction levels: It primarily comes down to easier access to care and lower costs.
TikTok health advice comes with a price: Here’s the danger lurking behind Gen Z’s practice of turning to TikTok for health advice and some recent developments that suggest help is on the way for younger social media users.
US adults report mixed comfort with healthcare AI: We unpack recent survey results and explore a potential pathway healthcare providers and AI developers can follow to address consumers’ AI-related concerns.
How pharma companies can build trust with physicians: Corporate brand messaging won’t drive doctors to prescribe meds. Docs want data on medications and information that will help them care for patients.
The state of digital health funding: A recent $200 million funding haul and IPO plans signal it may not be all doom and gloom in the post-pandemic era.